Keros Therapeutics (KROS) Other Non-Current Liabilities (2019 - 2021)

Keros Therapeutics has reported Other Non-Current Liabilities for 3 years, with the latest figure at $16000.0 in Q3 2021.

• For the quarter ending Q3 2021, Other Non-Current Liabilities fell 79.22% year-over-year to $16000.0; the trailing twelve-month figure through Sep 2021 stood at $16000.0 (down 79.22% YoY), and the FY2020 full-year result was $62000.0, down 47.9% from the prior year.
• Other Non-Current Liabilities for Q3 2021 stood at $16000.0, down from $32000.0 in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $119000.0 in Q4 2019, with the low at $16000.0 in Q3 2021.
• Historically, Other Non-Current Liabilities has averaged $68500.0 across 3 years, with a median of $69500.0 in 2020.
• Annual changes were most pronounced in 2020 — Other Non-Current Liabilities tumbled 47.9% — and 2021, when it sank 79.22%.
• Keros Therapeutics' Other Non-Current Liabilities stood at $119000.0 in 2019, then sank by 47.9% to $62000.0 in 2020, then slumped by 74.19% to $16000.0 in 2021.
• The last three Other Non-Current Liabilities figures came in at $16000.0 (Q3 2021), $32000.0 (Q2 2021), and $47000.0 (Q1 2021), per Business Quant data.